{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:55:12Z","timestamp":1770501312174,"version":"3.49.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1053\/bega.2003.0360","type":"journal-article","created":{"date-parts":[[2003,3,4]],"date-time":"2003-03-04T18:13:53Z","timestamp":1046801633000},"page":"119-130","source":"Crossref","is-referenced-by-count":15,"title":["New biological therapies in inflammatory bowel disease"],"prefix":"10.1053","volume":"17","author":[{"given":"S.J.H.","family":"van Deventer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/bega.2003.0360_RF1","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM200202213460812","article-title":"Genes, microbes, and T cells \u2013 new therapeutic targets in Crohn's disease","volume":"346","author":"Elson","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0360_RF2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1006\/smim.2001.0312","article-title":"Immuno-bacterial homeostasis in the gut: new insights into an old enigma","volume":"13","author":"Elson","year":"2001","journal-title":"Seminars in Immunology"},{"key":"10.1053\/bega.2003.0360_RF3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00054725-200005000-00008","article-title":"Bacterial regulation of intestinal immune responses","volume":"6","author":"MacDonald","year":"2000","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0360_RF4","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.4049\/jimmunol.165.9.5315","article-title":"Human Peyer's patch T cells are sensitized to dietary antigen and display a Th cell type 1 cytokine profile (in process citation)","volume":"165","author":"Nagata","year":"2000","journal-title":"Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.20.083001.084359","article-title":"Innate immune recognition","volume":"20","author":"Janeway","year":"2002","journal-title":"Annual Review of Immunology"},{"key":"10.1053\/bega.2003.0360_RF6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"10.1053\/bega.2003.0360_RF7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35051113","article-title":"ICOS is essential for effective T-helper-cell responses","volume":"409","author":"Tafuri","year":"2001","journal-title":"Nature"},{"key":"10.1053\/bega.2003.0360_RF8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation","volume":"19","author":"Salomon","year":"2001","journal-title":"Annual Review of Immunology"},{"key":"10.1053\/bega.2003.0360_RF9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1084\/jem.180.1.223","article-title":"B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation","volume":"180","author":"Murphy","year":"1994","journal-title":"Journal of Experimental Medicine"},{"key":"10.1053\/bega.2003.0360_RF10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1074-7613(02)00331-X","article-title":"Further checkpoints in Th1 development","volume":"16","author":"Robinson","year":"2002","journal-title":"Immunity"},{"key":"10.1053\/bega.2003.0360_RF11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/79758","article-title":"Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells","volume":"1","author":"Langenkamp","year":"2000","journal-title":"Nature Immunology"},{"key":"10.1053\/bega.2003.0360_RF12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annual Review of Immunology"},{"key":"10.1053\/bega.2003.0360_RF13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","article-title":"Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity","volume":"13","author":"Trinchieri","year":"1995","journal-title":"Annual Review of Immunology"},{"key":"10.1053\/bega.2003.0360_RF14","first-page":"5","article-title":"Mechanisms of peripheral T cell tolerance","volume":"215","author":"van Parijs","year":"1998","journal-title":"Novartis Foundation Symposium"},{"key":"10.1053\/bega.2003.0360_RF15","first-page":"997","article-title":"Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation","volume":"144","author":"Mazzucchelli","year":"1994","journal-title":"American Journal of Pathology"},{"key":"10.1053\/bega.2003.0360_RF16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1020583306627","article-title":"Chemokines in the inflammatory bowel diseases","volume":"19","author":"MacDermott","year":"1999","journal-title":"Journal of Clinical Immunology"},{"key":"10.1053\/bega.2003.0360_RF17","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/S0016-5085(97)70175-6","article-title":"The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease","volume":"113","author":"Z'Graggen","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000201043","article-title":"Ulcerative colitis serum recognizes the M(r) 40K protein on colonic adenocarcinoma cells for antibody-dependent cellular cytotoxicity","volume":"54","author":"Biancone","year":"1993","journal-title":"Digestion"},{"key":"10.1053\/bega.2003.0360_RF19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0016-5085(98)70310-5","article-title":"Tropomyosin isoforms in intestinal mucosa: Production of autoantibodies to tropomyosin isoforms in ulcerative colitis","volume":"114","author":"Geng","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF20","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/316552a0","article-title":"Identity of tumour necrosis factor and the macrophage-secreted factor cachectin","volume":"316","author":"Beutler","year":"1985","journal-title":"Nature"},{"key":"10.1053\/bega.2003.0360_RF21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.3895437","article-title":"Passive immunization against cachectin\/tumor necrosis factor protects mice from lethal effect of endotoxin","volume":"229","author":"Beutler","year":"1985","journal-title":"Science"},{"key":"10.1053\/bega.2003.0360_RF22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF02935501","article-title":"Cachectin\/tumor necrosis factor: an endogenous mediator of shock and inflammation","volume":"5","author":"Beutler","year":"1986","journal-title":"Immunologic Research"},{"key":"10.1053\/bega.2003.0360_RF23","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/330662a0","article-title":"Anti-cachectin\/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia","volume":"330","author":"Tracey","year":"1987","journal-title":"Nature"},{"key":"10.1053\/bega.2003.0360_RF24","first-page":"59","article-title":"Why immunomodulatory therapies have not worked in sepsis","volume":"29","author":"Abraham","year":"1999","journal-title":"Nursing"},{"key":"10.1053\/bega.2003.0360_RF25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"ii","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1053\/bega.2003.0360_RF26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clinical & Experimental Immunology"},{"key":"10.1053\/bega.2003.0360_RF27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF29","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor alpha for Crohns-disease","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0360_RF30","unstructured":"Rutgeerts, P, D'Haens, G, van Deventer, S, J, Retreatment with anti-TNF chimeric monoclonal antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease. Digestive Disease Week abstract book, 1997"},{"key":"10.1053\/bega.2003.0360_RF31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'Haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Ogilvie","year":"2001","journal-title":"British Journal of Dermatology"},{"key":"10.1053\/bega.2003.0360_RF33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"van den Bosch","year":"2000","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1053\/bega.2003.0360_RF34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1067\/mjd.2000.105948","article-title":"Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions","volume":"42","author":"Oh","year":"2000","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1053\/bega.2003.0360_RF35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/bega.2003.0360_RF36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(97)80083-9","article-title":"Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease","volume":"349","author":"Stack","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/bega.2003.0360_RF38","doi-asserted-by":"crossref","first-page":"A655","DOI":"10.1016\/S0016-5085(00)84760-5","article-title":"A randomized controlled trial of CDP571, a humanized antibody to TNFA, in moderately to severely active Crohn's disease","volume":"118","author":"Sandborn","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/rheumatology\/41.6.638","article-title":"Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha","volume":"41","author":"Den Broeder","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/bega.2003.0360_RF40","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.61.4.311","article-title":"Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation","volume":"61","author":"den Broeder","year":"2002","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1053\/bega.2003.0360_RF41","doi-asserted-by":"crossref","first-page":"i44","DOI":"10.1136\/ard.59.suppl_1.i44","article-title":"Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody","volume":"59","author":"Kempeni","year":"2000","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1053\/bega.2003.0360_RF42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/gast.2002.34172","article-title":"NOD2\/CARD15 does not influence response to infliximab in Crohn's disease","volume":"123","author":"Vermeire","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF43","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1053\/bega.2003.0360_RF44","first-page":"303","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis (see comments)","volume":"27","author":"Maini","year":"1998","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"10.1053\/bega.2003.0360_RF45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","article-title":"Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital","volume":"8","author":"Hommes","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0360_RF46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0360_RF47","first-page":"A","article-title":"Infliximab treatment allows Crohn's disease to reduce or discontinue comcomitant corticosteroid use: ACCENT I 1 year results","volume":"122","author":"Lichtenstein","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF48","first-page":"A","article-title":"Infliximab maintenance therapy improves health related quality of life (HRQL) in Crohn\u2032s disease over 54 weeks","volume":"122","author":"Feagan","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00002018-200023050-00006","article-title":"Comparative tolerability of treatments for inflammatory bowel disease","volume":"23","author":"Stein","year":"2000","journal-title":"Drug Safety"},{"key":"10.1053\/bega.2003.0360_RF50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00054725-199905000-00008","article-title":"Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety","volume":"5","author":"Sandborn","year":"1999","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0360_RF51","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1023\/A:1015326715456","article-title":"Anaphylaxis-like reaction to infliximab in a patient with Crohn's disease","volume":"47","author":"O'Connor","year":"2002","journal-title":"Digestive Disease Sciences"},{"key":"10.1053\/bega.2003.0360_RF52","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1067\/mpd.2002.123992","article-title":"Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease","volume":"140","author":"Diamanti","year":"2002","journal-title":"Journal of Pediatrics"},{"key":"10.1053\/bega.2003.0360_RF53","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00054725-200205000-00005","article-title":"Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion","volume":"8","author":"Riegert-Johnson","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0360_RF54","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis & Rheumatism"},{"key":"10.1053\/bega.2003.0360_RF55","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis & Rheumatism"},{"key":"10.1053\/bega.2003.0360_RF56","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1053\/bega.2003.0360_RF57","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/bega.2003.0360_RF58","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF59","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1053\/gast.2001.28702","article-title":"Infliximab induces apoptosis in monocytes from patients with chronic active crohn's disease by using a caspase-dependent pathway","volume":"121","author":"Lugering","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.1995.tb32327.x","article-title":"The soluble interleukin-6 receptor","volume":"762","author":"Rose-John","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1053\/bega.2003.0360_RF62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.1995.tb32328.x","article-title":"Membrane-bound and soluble interleukin-6 receptor: studies on structure, regulation of expression, and signal transduction","volume":"762","author":"Heinrich","year":"1995","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1053\/bega.2003.0360_RF63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130","volume":"58","author":"Taga","year":"1989","journal-title":"Cell"},{"key":"10.1053\/bega.2003.0360_RF64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nature Medicine"},{"key":"10.1053\/bega.2003.0360_RF65","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1471-4906(00)01798-1","article-title":"Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question","volume":"22","author":"Neurath","year":"2001","journal-title":"Trends in Immunology"},{"key":"10.1053\/bega.2003.0360_RF66","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"key":"10.1053\/bega.2003.0360_RF67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1998.tb08307.x","article-title":"Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme","volume":"856","author":"Dinarello","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1053\/bega.2003.0360_RF68","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.182.5.1281","article-title":"Antibodies to interleukin 12 abrogate established experimental colitis in mice","volume":"182","author":"Neurath","year":"1995","journal-title":"Journal of Experimental Medicine"},{"key":"10.1053\/bega.2003.0360_RF69","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/gast.2001.29579","article-title":"Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice","volume":"121","author":"Ten Hove","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF70","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S0016-5085(99)70392-6","article-title":"Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice","volume":"117","author":"Fuss","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF71","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/gut.32.4.403","article-title":"Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers","volume":"32","author":"Fais","year":"1991","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00054725-199811000-00005","article-title":"Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease","volume":"4","author":"Camoglio","year":"1998","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1053\/bega.2003.0360_RF73","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/(SICI)1521-4141(200005)30:5<1486::AID-IMMU1486>3.0.CO;2-8","article-title":"Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice","volume":"30","author":"Camoglio","year":"2000","journal-title":"European Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF74","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1046\/j.1365-2036.2002.01264.x","article-title":"Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial","volume":"16","author":"Musch","year":"2002","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1053\/bega.2003.0360_RF75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1749-6632.1998.tb08308.x","article-title":"Interleukin-11. A gp130 cytokine","volume":"856","author":"Trepicchio","year":"1998","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1053\/bega.2003.0360_RF76","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/sj.leu.2401514","article-title":"Hematopoietic, immunomodulatory and epithelial effects of interleukin-11","volume":"13","author":"Schwertschlag","year":"1999","journal-title":"Leukemia"},{"key":"10.1053\/bega.2003.0360_RF77","first-page":"1503","article-title":"Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease","volume":"78","author":"Peterson","year":"1998","journal-title":"Laboratory Investigation"},{"key":"10.1053\/bega.2003.0360_RF78","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2567.1998.00568.x","article-title":"An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis","volume":"95","author":"Walmsley","year":"1998","journal-title":"Immunology"},{"key":"10.1053\/bega.2003.0360_RF79","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","article-title":"Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease","volume":"117","author":"Sands","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-4615-1243-1_3","article-title":"Control of autoimmunity by regulatory T cells","volume":"490","author":"Shevach","year":"2001","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1053\/bega.2003.0360_RF81","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.4049\/jimmunol.166.6.3789","article-title":"IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo","volume":"166","author":"Hara","year":"2001","journal-title":"Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gut.42.2.157","article-title":"Interleukin 10 is a growth factor for a population of regulatory T cells","volume":"42","author":"Asseman","year":"1998","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF83","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/39614","article-title":"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis","volume":"389","author":"Groux","year":"1997","journal-title":"Nature"},{"key":"10.1053\/bega.2003.0360_RF84","doi-asserted-by":"crossref","first-page":"900","DOI":"10.4049\/jimmunol.168.2.900","article-title":"The interrelated roles of TGF--beta and IL-10 in the regulation of experimental colitis","volume":"168","author":"Fuss","year":"2002","journal-title":"Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF85","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/1521-4141(200007)30:7<2101::AID-IMMU2101>3.0.CO;2-P","article-title":"The effect of TGF-beta1 on immune responses of naive versus memory CD4+Th1\/Th2 T cells","volume":"30","author":"Ludviksson","year":"2000","journal-title":"European Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-3083.2001.00945.x","article-title":"Non-Th2 regulatory T-cell control of Th1 autoimmunity","volume":"54","author":"Bach","year":"2001","journal-title":"Scandinavian Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF87","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1034\/j.1600-065X.2001.1820117.x","article-title":"Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells","volume":"182","author":"Weiner","year":"2001","journal-title":"Immunology Reviews"},{"key":"10.1053\/bega.2003.0360_RF88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/gast.1997.v113.pm9247454","article-title":"Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease","volume":"113","author":"van Deventer","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF89","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1053\/gast.2000.20229","article-title":"Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease","volume":"119","author":"Fedorak","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF90","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1053\/gast.2000.20196","article-title":"Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease","volume":"119","author":"Schreiber","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF91","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/gut.50.2.191","article-title":"Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma","volume":"50","author":"Tilg","year":"2002","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF92","first-page":"888","article-title":"Proinflammatory effects of IL-10 during human endotoxemia","volume":"182","author":"Lauw","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1053\/bega.2003.0360_RF93","doi-asserted-by":"crossref","first-page":"A873","DOI":"10.1016\/S0016-5085(00)85633-4","article-title":"Therapeutic potential of genetically modified T-lymphocytes in Crohn's disease","volume":"118","author":"Te Velde","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gut.40.3.320","article-title":"CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study","volume":"40","author":"Stronkhorst","year":"1997","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF95","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/eji.1830220735","article-title":"The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice","volume":"22","author":"Hutchings","year":"1992","journal-title":"European Journal of Immunology"},{"key":"10.1053\/bega.2003.0360_RF96","first-page":"2065","article-title":"Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4","volume":"25","author":"Schulze-Koops","year":"1998","journal-title":"Journal of Rheumatology"},{"key":"10.1053\/bega.2003.0360_RF97","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1182\/blood.V95.12.3693","article-title":"A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease","volume":"95","author":"van Oosterhout","year":"2000","journal-title":"Blood"},{"key":"10.1053\/bega.2003.0360_RF98","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(98)84222-4","article-title":"Low ileal IL-10 mRNA levels may predict endoscopic recurrence after surgery in a subgroup of patients with Crohn's disease (CD)","volume":"114","author":"Meresse","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF99","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.193.7.827","article-title":"Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)\/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies","volume":"193","author":"Desreumaux","year":"2001","journal-title":"Journal of Experimental Medicine"},{"key":"10.1053\/bega.2003.0360_RF100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gut.50.4.507","article-title":"Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1053\/bega.2003.0360_RF101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/gast.2002.30770","article-title":"Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease","volume":"122","author":"Hommes","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/bega.2003.0360_RF102","first-page":"3323","article-title":"An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis","volume":"96","author":"Lewis","year":"2001","journal-title":"American Journal of Gastroenterology"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180390360X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180390360X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,17]],"date-time":"2020-03-17T19:49:17Z","timestamp":1584474557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169180390360X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S152169180390360X"],"URL":"https:\/\/doi.org\/10.1053\/bega.2003.0360","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}